Compare PRTA & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | ADV |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.4M | 523.2M |
| IPO Year | 2013 | 2019 |
| Metric | PRTA | ADV |
|---|---|---|
| Price | $8.36 | $33.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $19.00 | ★ $45.83 |
| AVG Volume (30 Days) | ★ 307.4K | 57.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | $814,000.00 | ★ $3,542,642,000.00 |
| Revenue This Year | $1,111.38 | $0.63 |
| Revenue Next Year | N/A | $0.45 |
| P/E Ratio | $34.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $0.49 |
| 52 Week High | $11.80 | $47.45 |
| Indicator | PRTA | ADV |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 49.96 |
| Support Level | $8.62 | $33.26 |
| Resistance Level | $9.36 | $35.50 |
| Average True Range (ATR) | 0.33 | 1.74 |
| MACD | -0.08 | 0.23 |
| Stochastic Oscillator | 8.60 | 65.29 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.